Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 9, 2026, 3:16 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: IBS Clear all
Not yet recruiting Not applicable Interventional

The Mechanism Underlying the Analgesic Effect of the Music of IBS Pain

NCT06706778
View directory record Official record
Conditions
Abdominal Pain/ Discomfort, Irritable Bowel Syndrome
Interventions
Music intervention
Behavioral
Lead sponsor
Yale University
Other
Eligibility
18 Years to 50 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Sep 9, 2026, 3:16 AM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

Temple Registry for the Investigation of African American Gastrointestinal Disease Epidemiology

NCT01262755
View directory record Official record
Conditions
Gastroesophageal Reflux Disease, Functional Bowel Disorders
Interventions
Structured Interview
Behavioral
Lead sponsor
Temple University
Other
Eligibility
18 Years to 80 Years
Enrollment
450 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2015
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 3, 2015 · Synced Sep 9, 2026, 3:16 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

SBI in Children With d-IBS

NCT02609529
View directory record Official record
Conditions
Irritable Bowel Syndrome
Interventions
Medical Food, Placebo
Other
Lead sponsor
Louisiana State University Health Sciences Center in New Orleans
Other
Eligibility
8 Years to 18 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Mar 8, 2017 · Synced Sep 9, 2026, 3:16 AM EDT
Completed Not applicable Interventional

Relaxation Music for Chronic Pain

NCT06993272
View directory record Official record
Conditions
IBS - Irritable Bowel Syndrome, IBD - Inflammatory Bowel Disease
Interventions
MIndful Jazz, Reggae Stereotypes, Traditional Mindfulness, Pain psychoeducation
Behavioral
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Sep 9, 2026, 3:16 AM EDT
Recruiting Phase 2 Interventional

A Study of Brenipatide (LY3537031) in Participants With Irritable Bowel Syndrome-Constipation (IBS-C)

NCT07545772
View directory record Official record
Conditions
Irritable Bowel Syndrome, Constipation
Interventions
LY3537031, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 75 Years
Enrollment
342 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
14
States / cities
Mesa, Arizona • Anaheim, California • Lancaster, California + 11 more
Source: ClinicalTrials.gov public record
Updated Sep 7, 2026 · Synced Sep 9, 2026, 3:16 AM EDT
Completed Phase 2 Interventional Results available

A Study of the Effect of SYN-010 on Subjects With IBS-C

NCT02495623
View directory record Official record
Conditions
Irritable Bowel Syndrome With Constipation (IBS-C)
Interventions
SYN-010 21 mg, SYN-010 42 mg, Placebo
Drug
Lead sponsor
Theriva Biologics, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Nov 26, 2018 · Synced Sep 9, 2026, 3:16 AM EDT
Completed No phase listed Observational

Retrospective Study of IBS-D Patients Previously Receiving SBI

NCT02661425
View directory record Official record
Conditions
Diarrhoea Predominant Irritable Bowel Syndrome
Interventions
EnteraGam
Other
Lead sponsor
Entera Health, Inc
Industry
Eligibility
18 Years and older
Enrollment
165 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
16
States / cities
Greenwich, Connecticut • Hamdon, Connecticut • Coral Springs, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2016 · Synced Sep 9, 2026, 3:16 AM EDT
Completed Not applicable Interventional Results available

Effect of Tai Chi as Treatment for IBS-C

NCT04132804
View directory record Official record
Conditions
Irritable Bowel Syndrome With Constipation
Interventions
Tai Chi
Behavioral
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 70 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Sep 9, 2026, 3:16 AM EDT
Completed Phase 3 Interventional

Study of Asimadoline to Treat Diarrhea-Predominant Irritable Bowel Syndrome (D-IBS)

NCT01100684
View directory record Official record
Conditions
Diarrhea Predominant Irritable Bowel Syndrome
Interventions
Asimadoline, Placebo
Drug
Lead sponsor
Tioga Pharmaceuticals
Industry
Eligibility
18 Years to 79 Years
Enrollment
611 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
142
States / cities
Athens, Alabama • Birmingham, Alabama • Huntsville, Alabama + 125 more
Source: ClinicalTrials.gov public record
Updated Dec 17, 2013 · Synced Sep 9, 2026, 3:16 AM EDT
Terminated Phase 2 Interventional

Use of Novel Prebiotic Fiber for Targeted Dietary Management of Irritable Bowel Syndrome (Nutrabiotix Phase II)

NCT02144753
View directory record Official record
Conditions
Constipation-predominant IBS (IBS-C)
Interventions
NTX-1, psyllium (15 g)
Dietary Supplement · Drug
Lead sponsor
Nutrabiotix, LLC
Industry
Eligibility
18 Years to 75 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 1, 2016 · Synced Sep 9, 2026, 3:16 AM EDT
Completed Not applicable Interventional Results available

The Role of Fiber in the Prevention and Treatment of Fecal Incontinence

NCT04806386
View directory record Official record
Conditions
Fecal Incontinence, Irritable Bowel Syndrome With Diarrhea
Interventions
Psyllium
Dietary Supplement
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
50 Years to 90 Years · Female only
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Sep 9, 2026, 3:16 AM EDT
Recruiting Early Phase 1 Interventional

Novel Pilot Study to Treat Symptoms of IBS With Diarrhea Using Combination Therapy of a Low-FODMAP Diet and a Neuromodulator

NCT06684470
View directory record Official record
Conditions
IBS - Irritable Bowel Syndrome, Diarrhea
Interventions
Mirtazapine, Placebo
Drug · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 70 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Dec 17, 2025 · Synced Sep 9, 2026, 3:16 AM EDT
Active, not recruiting Phase 3 Interventional

Study to Assess Safety and Efficacy of Tenapanor for Treatment of IBS-C in Pediatric Patients 12 to Less Than 18 Years

NCT05643534
View directory record Official record
Conditions
Irritable Bowel Syndrome With Constipation (IBS-C)
Interventions
Tenapanor 50 MG, Tenapanor 25 mg bid, Placebo
Drug
Lead sponsor
Ardelyx
Industry
Eligibility
12 Years to 17 Years
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
39
States / cities
Foley, Alabama • Tucson, Arizona • Little Rock, Arkansas + 34 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Sep 9, 2026, 3:16 AM EDT
Completed Phase 2 Interventional Results available

Randomized, Double-blind, Dose-range-finding, Phase 2 Study of Linaclotide Administered to Patients With Irritable Bowel Syndrome With Constipation (IBS-C)

NCT00460811
View directory record Official record
Conditions
Irritable Bowel Syndrome With Constipation
Interventions
Linaclotide Acetate, Matching placebo
Drug
Lead sponsor
Ironwood Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
420 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
79
States / cities
Huntsville, Alabama • Chandler, Arizona • Tuscon, Arizona + 76 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2013 · Synced Sep 9, 2026, 3:16 AM EDT
Completed Phase 4 Interventional

Paroxetine - Controlled Release in the Treatment of Irritable Bowel Syndrome (IBS)

NCT00610909
View directory record Official record
Conditions
Irritable Bowel Syndrome
Interventions
Paroxetine CR, Placebo
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years to 75 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 19, 2013 · Synced Sep 9, 2026, 3:16 AM EDT
Terminated Phase 2Phase 3 Interventional Results available

Effect of Ranolazine on Gastrointestinal Motor Function and Pain in Patients With IBS-D

NCT02239926
View directory record Official record
Conditions
Diarrhea Predominant Irritable Bowel Syndrome
Interventions
Ranolazine, Placebo
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 70 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 14, 2016 · Synced Sep 9, 2026, 3:16 AM EDT
Terminated Phase 2 Interventional

Study to Evaluate the Effects of ONO-2952 on Pain Perception Produced by Rectal Distention in Female Subjects With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D)

NCT01887002
View directory record Official record
Conditions
Irritable Bowel Syndrome (IBS)
Interventions
ONO-2952, Placebo comparator
Drug
Lead sponsor
Ono Pharma USA Inc
Industry
Eligibility
18 Years to 65 Years · Female only
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2013
U.S. locations
4
States / cities
Boston, Massachusetts • St Louis, Missouri • Chapel Hill, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 24, 2016 · Synced Sep 9, 2026, 3:16 AM EDT
Completed Phase 3 Interventional Results available

Long Term Safety Study of Plecanatide

NCT02706483
View directory record Official record
Conditions
Irritable Bowel Syndrome
Interventions
Plecanatide
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
2,272 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
204
States / cities
Athens, Alabama • Birmingham, Alabama • Dothan, Alabama + 200 more
Source: ClinicalTrials.gov public record
Updated Aug 17, 2020 · Synced Sep 9, 2026, 3:16 AM EDT
Completed Phase 3 Interventional

Treatment of Functional Bowel Disorders

NCT00006157
View directory record Official record
Conditions
Irritable Bowel Syndrome, Constipation, Abdominal Pain, Functional Colonic Diseases
Interventions
Desipramine, Cognitive Behavioral Treatment
Drug · Behavioral
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years to 65 Years · Female only
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2001
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 12, 2010 · Synced Sep 9, 2026, 3:16 AM EDT
Completed Phase 2 Interventional Results available

Randomized Placebo Controlled Efficacy And Safety Study Investigating GW876008 In Patients With Irritable Bowel Syndrome

NCT00421707
View directory record Official record
Conditions
Irritable Bowel Syndrome (IBS)
Interventions
GW876008, Placebo
Drug · Other
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 64 Years
Enrollment
133 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
17
States / cities
Sherwood, Arkansas • Concord, California • Los Angeles, California + 14 more
Source: ClinicalTrials.gov public record
Updated Jan 30, 2018 · Synced Sep 9, 2026, 3:16 AM EDT
Suspended Phase 2 Interventional

A Four Arm Study to Evaluate the Safety and Efficacy of 3 Different Doses of RVX-100 Versus Placebo in Subjects With Irritable Bowel Syndrome Accompanied by Diarrhea (IBS-D)

NCT01076699
View directory record Official record
Conditions
Irritable Bowel Syndrome
Interventions
0.075 mg RVX-100, 0.125 mg RVX-100, 0.250 mg RVX-100, placebo
Drug
Lead sponsor
Revogenex, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
192 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Chevy Chase, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 18, 2010 · Synced Sep 9, 2026, 3:16 AM EDT
Completed Not applicable Interventional Results available

Efficacy of Open Label Placebo in Children With FGIDs

NCT02389998
View directory record Official record
Conditions
Functional Abdominal Pain, Functional Dyspepsia, Irritable Bowel Syndrome, Functional Gastrointestinal Disorders
Interventions
Placebo Suspension, Hyoscyamine
Other · Drug
Lead sponsor
Boston Children's Hospital
Other
Eligibility
8 Years to 21 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 22, 2021 · Synced Sep 9, 2026, 3:16 AM EDT
Terminated Not applicable Interventional

Effect of Acupuncture on Symptoms of Diarrhea and Pain in IBS

NCT00219505
View directory record Official record
Conditions
Irritable Bowel Syndrome
Interventions
acupuncture
Procedure
Lead sponsor
Penn State University
Other
Eligibility
18 Years to 90 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2004
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 23, 2017 · Synced Sep 9, 2026, 3:16 AM EDT
Completed Phase 3 Interventional Results available

A Long-Term Safety Study of Tenapanor for the Treatment of IBS-C

NCT02727751
View directory record Official record
Conditions
Constipation Predominant Irritable Bowel Syndrome
Interventions
Tenapanor
Drug
Lead sponsor
Ardelyx
Industry
Eligibility
18 Years to 75 Years
Enrollment
312 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Sep 8, 2020 · Synced Sep 9, 2026, 3:16 AM EDT